1 completed, 1 recruiting, 1 withdrawn. 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 1, Recruiting 1, Withdrawn 1 |
| Phase 1 | 2 | Recruiting 1, Withdrawn 1 |
Follow C188-9 compound: new trials by email Literature Review of C188-9 compound trials Research Report on C188-9 compound
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3 Inhibition (TTI-101) With Anti-PD-1 Therapy (Pembrolizumab) in Patients With Recurrent or Metastatic (RM) Head and Neck Squamous Cell Carcinoma (HNSCC) TTI-101, Pembrolizumab - Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2025-09-23 | 2025-12-17 | |
| Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis TTI-101, Placebo - Idiopathic Pulmonary Fibrosis | Phase 2 | Completed | Tvardi Therapeutics, Incorporated | 100 | 2023-05-15 | 2026-08-13 |
| A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma TTI-101, Pembrolizumab, Atezolizumab - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Recruiting | Tvardi Therapeutics, Incorporated | 193 | 2023-03-23 | 2026-10-22 |
Carcinoma, Hepatocellular (1) · Idiopathic Pulmonary Fibrosis (1) · Squamous Cell Carcinoma of Head and Neck (1)
Tvardi Therapeutics, Incorporated (2) · M.D. Anderson Cancer Center (1)
United States (2)
Faye Johnson, MD (1)